

SAMSRITA LABS LIMITED

To,

Date: 06.02.2026

1. BSE Limited P.J. Towers, Dalal Street, Mumbai-400 001 Scrip Code: 539267	2. Metropolitan Stock Exchange of India Limited 205(A), 2 nd Floor, Piramal Agastya Corporate Park, Kamani Junction, LBS Road, Kurla (West), Mumbai-400 070 Symbol: SAMSRITA
--	--

Sub: Outcome of Board Meeting held on 06.02.2026 under Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015

Unit: Samsrita Labs Limited

Dear Sir/Madam,

With reference to the above mentioned subject, this is to inform the Exchanges that at the meeting of the Board of Directors of Samsrita Labs Limited held on Friday, the 06th day of February, 2026 at 3.30 P.M. at the registered office of the Company situated at 6-3-354/13/B2, Flat. No. B2, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad-500082, Telangana the following was considered and approved:

1. Un-audited Standalone and Consolidated financial results for the quarter and nine months ended 31.12.2025 along with the Limited Review Reports as per Regulation 33 of SEBI (LODR) Regulations, 2015 (Enclosed)
2. To write-off Intangible Assets under development of Rs.3,25,95,369/- as no longer Potential benefit to the Company.

The meeting concluded at 4.00 p.m.

Thanking you,

Yours sincerely

For Samsrita Labs Limited

K. Krishnam Raju
Chairman & Whole-time Director
DIN: 00874650

Encl: As above

PART-I							(Rs in Lakhs)
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER III AND 9 MONTHS ENDED 31ST DECEMBER, 2025							
Sr.No	Particulars	Quarter ended			Nine Months Ended		Previous Year ended 31-03-2025
		3 Months ended 31-12-2025	Corresponding 3 months ended in previous year 31-12-2024	Preceding 3 months ended 30-09-2025	For current period 9 Months ended 31-12-2025	For previous period 9 Months ended 31-12-2024	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
I	Revenue from Operations	-	-	-	-	-	-
II	Other Income	-	-	-	-	-	-
III	Total Revenue (I+II)	-	-	-	-	-	-
IV	Expenses						
	Cost of Material Consumed	-	-	-	-	-	-
	Employee benefits expense	5.32	2.76	10.43	31.28	8.28	13.14
	Depreciation and Amortisation expense	0.03	0.03	0.03	0.10	0.10	0.14
	Other Expenses	330.21	1.26	483.04	825.34	8.87	12.67
	Total Expenses	335.56	4.05	493.50	856.72	17.25	25.95
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(335.56)	(4.05)	(493.50)	(856.72)	(17.25)	(25.95)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(335.56)	(4.05)	(493.50)	(856.72)	(17.25)	(25.95)
VIII	Tax Expense:	-	-	-	-	-	-
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(335.56)	(4.05)	(493.50)	(856.72)	(17.25)	(25.95)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(335.56)	(4.05)	(493.50)	(856.72)	(17.25)	(25.95)
XIV	Other Comprehensive Income						
	A) (i) Items that will not be reclassified to profit or loss						
	(ii) Income Tax related to items that will not be reclassified to profit or loss						
	B) (i) Items that will be reclassified to profit or loss						
	(ii) Income Tax relating to items that will be reclassified to profit or loss						
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(335.56)	(4.05)	(493.50)	(856.72)	(17.25)	(25.95)
XVI	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)						
	1) Basic	(1.48)	(0.03)	(2.17)	(4.36)	(0.12)	(0.18)
	2) Diluted	(1.48)	(0.03)	(2.17)	(4.36)	(0.12)	(0.18)
XVII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)						
	1) Basic	-	-	-	-	-	-
	2) Diluted	-	-	-	-	-	-
XVIII	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)						
	1) Basic	(1.48)	(0.03)	(2.17)	(4.36)	(0.12)	(0.18)
	2) Diluted	(1.48)	(0.03)	(2.17)	(4.36)	(0.12)	(0.18)
XIX	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	2,274.97	1480.87	2,274.97	2,274.97	1,480.87	1480.87

Notes:

- The Unaudited Standalone financial results for the Quarter III and 9 months period ended 31, December 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on Friday, February 6th, 2026. The Statutory Auditors have carried out the Limited Review of the Unaudited Standalone Financial Results in accordance with Regulation 33 of SEBI (LODR) Regulations, 2015).
- The unaudited Standalone financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of Companies Act, 2013 and other accounting principles generally accepted in India and in terms Regulation 33 of SEBI (LODR) Regulations, 2015.
- The Company has only one reportable segment as per requirements of AS 108 "Operating Segments" i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- During the quarter, the company has written off ₹3,25,95,369 (Rs Three crores twenty five lakhs ninety five thousand three hundred sixty nine only) relating to intangible assets under development. This adjustment was necessitated by technological obsolescence etc., as the underlying patents are no longer expected to provide future economic benefits to the company."
- The figures of the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.

Place : Hyderabad
Date : 06/02/2026

For SAMSRITA LABS LIMITED

K. Krishnam Raju
Chairman & Whole-time Director (DIN: 00874650)





Independent Auditor's Review Report on unaudited Standalone Quarterly Financial results of Samsrita labs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Samsrita Labs Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Samsrita Labs Limited ("the Company") for the quarter ended December 31, 2025 and year to date results for the period April 01, 2025 to December 31, 2025 ("the Statement") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")

2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion.

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.





5. Emphasis of Matters

We draw attention to the following points:

During the quarter ended 31.12.2025, the Company has written off intangible assets under development amounting to ₹3,25,95,369.71, due to technological obsolescence and is no longer expected to generate future economic benefits.

The write-off has been recognized in the Statement of Profit and Loss for the quarter.

Our Conclusion is not modified in respect of this matter.

For MGR & CO
Chartered Accountants
FRN:012787S

M.G Rao

M.G Rao
Partner

M.No.029893

UDIN: 26029893JDORO08330

Place: Hyderabad

Date: 06.02.2026



PART-I						(Rs in Lakhs)	
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER III AND 9 MONTHS ENDED 31ST DECEMBER, 2025							
Sr.No	Particulars	Quarter ended			Nine Months Ended		Previous Year ended 31-03-2025
		3 Months ended 31-12-2025	Corresponding 3 months ended in previous year 31-12-2024	Preceding 3 months ended 30-09-2025	For current period 9 Months ended 31-12-2025	For previous period 9 Months ended 31-12-2024	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
I	Revenue from Operations	-	-	-	-	-	-
II	Other Income	-	-	-	-	-	-
III	Total Revenue (I+II)	-	-	-	-	-	-
IV	Expenses						
	Cost of Material Consumed	-	-	-	-	-	-
	Employee benefits expense	5.32	-	10.43	31.28	-	-
	Depreciation and Amortisation expense	0.03	-	0.03	0.10	-	-
	Other Expenses	330.21	-	483.04	825.34	-	-
	Total Expenses	335.56	-	493.50	856.72	-	-
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(335.56)	-	(493.50)	(856.72)	-	-
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(335.56)	-	(493.50)	(856.72)	-	-
VIII	Tax Expense:						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(335.56)	-	(493.50)	(856.72)	-	-
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-	-
XIII	Share of Profit (loss) of Associates and Joint ventures accounted for using equity method	41.62	-	38.73	85.41	-	-
XIV	Profit/ (Loss) for the period (IX+XIII)	(293.94)	-	(454.77)	(771.31)	-	-
XV	Other Comprehensive Income						
	A) (i) Items that will not be reclassified to profit or loss						
	(ii) Income Tax related to items that will not be reclassified to profit or loss						
	B) (i) Items that will be reclassified to profit or loss						
	(ii) Income Tax relating to items that will be reclassified to profit or loss						
XVI	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(293.94)	-	(454.77)	(771.31)	-	-
XVII	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)						
	1) Basic	(1.29)	-	(2.00)	(3.92)	-	-
	2) Diluted	(1.29)	-	(2.00)	(3.92)	-	-
XVIII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)						
	1) Basic	-	-	-	-	-	-
	2) Diluted	-	-	-	-	-	-
XIX	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)						
	1) Basic	(1.29)	-	(2.00)	(3.92)	-	-
XX	2) Diluted	(1.29)	-	(2.00)	(3.92)	-	-
	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	2,274.97	-	2,274.97	2,274.97	-	-


Notes:

- The Unaudited Consolidated financial results for the Quarter III and 9 months period ended 31, December 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on Friday, February 6th, 2026. The Statutory Auditors have carried out the Limited Review of the Unaudited Standalone Financial Results in accordance with Regulation 33 of SEBI (LODR) Regulations, 2015).
- The unaudited Consolidated financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of Companies Act, 2013 and other accounting principles generally accepted in India and in terms Regulation 33 of SEBI (LODR) Regulations, 2015.
- The Company has only one reportable segment as per requirements of AS 108 "Operating Segments" i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- During the quarter, the company has written off ₹3,25,95,369 (Rs Three crores twenty five lakhs ninety five thousand three hundred sixty nine only) relating to intangible assets under development. This adjustment was necessitated by technological obsolescence etc., as the underlying patents are no longer expected to provide future economic benefits to the company."
- The figures of the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.

Place : Hyderabad
Date : 06/02/2026

For SAMSRITA LABS LIMITED

K. Krishnam Raju
Chairman & Whole-time Director (DIN: 00874650)





Independent Auditor's Review Report on unaudited Consolidated Quarterly Financial results of Samsrita labs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Samsrita Labs Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Samsrita Labs Limited ("the Company") for the quarter ended December 31,2025 and year to date results for the period April 01,2025 to December 31,2025 ("the Statement") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", Ind AS 110 "Consolidated Financial Statements" and Ind AS 28 "Investments in Associates and Joint Ventures" prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion.
4. The Statement includes the interim financial results of two associate companies, Krisani Biosciences Private Limited, whose interim financial results reflect total loss of ₹ 1200 out of





which the company's share of the profit is based on its ownership interest of 32.91% i.e ₹ 394.92 and Qrops Advisory Services Private Limited, whose interim financial results reflect total profit of ₹ 1,45,42,765 out of which the company's share of the profit is based on its ownership interest of 28.62% i.e ₹ 41,62,139.34 for the quarter ended 31 December 2025, as considered in the Statement. These financial results have not been reviewed by us. The reports have been furnished to us by the management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these associates, is based solely on the financials provided by the management and the procedures performed by us as stated in paragraph 3 above.

5. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, ", Ind AS 110 "Consolidated Financial Statements" and Ind AS 28 "Investments in Associates and Joint Ventures" Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Emphasis of Matters

We draw attention to the following :

During the quarter ended 31.12.2025, the Company has written off intangible assets under development amounting to ₹3,25,95,369.71, due to technological obsolescence and is no longer expected to generate future economic benefits.

The write-off has been recognized in the Statement of Profit and Loss for the quarter.

Our Conclusion is not modified in respect of this matter.

For MGR & CO
Chartered Accountants
FRN:012787S

M.G Rao

M.G Rao
Partner

M.No.029893

UDIN: 26029893MEDNCE6288

Place: Hyderabad

Date:06.02.2026

